Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Med Mushrooms ; 23(5): 1-11, 2021.
Article in English | MEDLINE | ID: mdl-34347990

ABSTRACT

Since December 2019, a de novo pattern of pneumonia, later named coronavirus disease 2019 (COVID-19), has caused grave upset throughout the global population. COVID-19 is associated with several comorbidities; thus, preventive and therapeutic strategies targeting those comorbidities along with the causative agent, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), seem imperative. In this state-of-the-art review, edible and medicinal mushrooms are featured in the treatment of SARS-CoV-2, COVID-19 pathomanifestations, and comorbid issues. Because this is not an original research article, we admit our shortcomings in inferences. Yet we are hopeful that mushroom-based therapeutic approaches can be used to achieve a COVID-free world. Among various mushroom species, reishi or lingzhi (Ganoderma lucidum) seem most suitable as anti-COVID agents for the global population.


Subject(s)
Agaricales/chemistry , Antiviral Agents/therapeutic use , Biological Products/therapeutic use , COVID-19/prevention & control , COVID-19/therapy , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , Antiviral Agents/administration & dosage , Biological Products/administration & dosage , COVID-19/immunology , COVID-19/physiopathology , Cytokine Release Syndrome/prevention & control , Cytokine Release Syndrome/therapy , Humans , Immunologic Factors/administration & dosage , Immunologic Factors/therapeutic use , Mice , Reishi/chemistry , SARS-CoV-2/immunology , SARS-CoV-2/pathogenicity
SELECTION OF CITATIONS
SEARCH DETAIL
...